Perrigo Q4 Sales Slide 2.5% to $1.11B, EPS Falls to $0.77
Perrigo’s Q4 net sales fell 2.5% to $1.11 billion as organic revenue dipped 4.5%, driving adjusted EPS down to $0.77 from $0.93 a year ago. Fiscal 2025 net sales declined 2.8% to $4.25 billion while adjusted EPS rose 7% to $2.75, and the 2026 outlook targets sales down 1.5%–5.5% with EPS of $2.00–$2.30.
1. Q4 and Fiscal 2025 Performance
For the quarter ended December 31, 2025, Perrigo reported net sales of $1.11 billion, down 2.5% year-over-year, with organic net sales falling 4.5% primarily due to weaker infant formula demand. Adjusted EPS was $0.77 versus $0.93 in the prior year, while operating cash flow for the full year reached $239 million and cash on hand totaled $532 million.
2. Operational Enhancement Program
Perrigo advanced its ‘3-S Plan’ by boosting store brand OTC and key brand market share in core categories and rolling out a new operational enhancement program expected to deliver $80 million to $100 million in annual pre-tax savings. These initiatives aim to streamline complexity and strengthen profitability across its consumer health portfolio.
3. Fiscal 2026 Outlook and Reporting Changes
The company issued an ‘All In’ 2026 outlook calling for net sales down 5.5% to 1.5% with adjusted EPS of $2.00–$2.30, and a ‘CORE’ outlook—excluding infant formula and divested businesses—projecting net sales down 3% to up 1% with adjusted EPS of $2.25–$2.55. Perrigo will adopt new reporting segments aligned to its commercial operating model beginning Q1 2026.